Briviact is the newest antiepileptic drug (AED) in the
'racetam' class of medicines and demonstrates a high and
selective affinity for synaptic vesicle protein 2A (SV2A) in
the brain, which may contribute to its anticonvulsant effects.
Gradual dose escalation is not required when initiating
treatment with Briviact for monotherapy or adjunctive therapy,
allowing clinicians to initiate treatment at a therapeutic dose
from day one.
The emergence of disruptive mobile health (mHealth)
technologies like Fitbit, Apple Watch, Telcare, and Scanadu
is fueling an industry push towards a more patient-centered
approach in clinical trials.
This approach (also known as site-less trials, remote trials,
and virtual trials) utilizes mHealth devices to allow patients
to transmit remote, real-time data (e.g., sleep duration and
quality, blood pressure, blood sugar, activity levels, heart rate,
etc.) directly to the central study site. Volunteers communicate
with study personnel remotely via technology and receive their
medications in the mail.
New Treatment Option Approved
For Epilepsy Patients 16 Years
Of Age Or Older
Are Site-Less Trials
The Future Of Clinical
Genentech’s Breast Cancer
early s nt
CDMO Recipharm Signs Manufacturing
Agreement With Roche
will acquire a
people located in
from Roche. The
modern, well-equipped factory,
located close to
produces solid dose products and is licensed to supply
products globally to more than 95 countries.
"We are continuing to gain momentum in the CDMO market
through our various profitable growth initiatives,” said Thomas
Eldered, CEO Recipharm AB.